The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 16, 2017
Filed:
Apr. 19, 2013
Joseph T. Bruder, Ijamsville, MD (US);
Imre Kovesdi, Rockville, MD (US);
Duncan L. Mcvey, Derwood, MD (US);
Douglas E. Brough, Gaithersburg, MD (US);
C. Richter King, Washington, DC (US);
Denise Louise Doolan, Camp Hill, AU;
Joao Carlos Aguair, Potomac, MD (US);
Daniel John Carucci, Washington, DC (US);
Martha Sedegah, Gaithersburg, MD (US);
Walter R. Weiss, Bethesda, MD (US);
Keith Limbach, Gaithersburg, MD (US);
Joseph T. Bruder, Ijamsville, MD (US);
Imre Kovesdi, Rockville, MD (US);
Duncan L. McVey, Derwood, MD (US);
Douglas E. Brough, Gaithersburg, MD (US);
C. Richter King, Washington, DC (US);
Denise Louise Doolan, Camp Hill, AU;
Joao Carlos Aguair, Potomac, MD (US);
Daniel John Carucci, Washington, DC (US);
Martha Sedegah, Gaithersburg, MD (US);
Walter R. Weiss, Bethesda, MD (US);
Keith Limbach, Gaithersburg, MD (US);
The United States of America as Represented by the Secretary of the Navy, Washington, DC (US);
Abstract
The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.